Tumor Biology

, Volume 35, Issue 12, pp 12655–12664 | Cite as

Significance of −1082A/G polymorphism of IL10 gene for progression of colorectal cancer and IL-10 expression

  • Lyuba D. Miteva
  • Noyko S. Stanilov
  • Tashko S. Deliysky
  • Spaska A. Stanilova
Research Article


The role of functional polymorphism within IL10 (rs1800896) in colorectal cancer (CRC) still remains elusive. The aim of present study was to investigate the significance of −1082A/G polymorphism in IL10 on CRC risk, progression, and overall survival in a cohort of Bulgarian patients. Also, a functional role of this polymorphism on systemic and local level of IL10 mRNA quantity and serum IL-10 level was explored. A group of 119 patients with sporadic CRC and 154 age-sex-matched controls were genotyped by allele-specific PCR. The quantification of mRNA and serum IL-10 levels was performed by real-time PCR and ELISA assays, respectively. The genotype and allelic frequency among cases and controls was similar. However, we observed significant elevation of G-allele and GG-genotype frequencies among advanced CRC. G-allele was overrepresented in advanced CRC patients (49 %) compared to early CRC (35 %) with OR = 1.77; 95%CI 1.018 ÷ 3.083; P = 0.031. A significant upregulated expression of IL10 mRNA was observed among AG/GG-genotypes in tumor tissue compared to homozygous AA-genotype (RQ value 68.3 vs. 6.68; P = 0.0062). Also, GG-genotype of −1082A/G polymorphism in IL10 was positively associated with higher serum IL-10 among early CRC patients and controls, in contrast to advanced cases. Although, investigated polymorphism in IL10 has no significant impact of overall survival among Bulgarian CRC patients, we found a significant relationship of high pre-operative serum level of IL-10 with poor survival of CRC (P = 0.023). Our findings indicate a significant impact of −1082A/G polymorphism of IL10 on CRC progression, rather than genetic predisposition and prognosis of CRC.


rs1800896 Tumor mRNA Serum 



This work was supported by Grants: no. 4/2009, 3/2013, and 1/2014 from the Fund for Scientific and Mobile project from Faculty of Medicine at the Trakia University, Stara Zagora, Bulgaria.

Conflicts of interest



  1. 1.
    Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–14.e5.PubMedCrossRefGoogle Scholar
  2. 2.
    Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.PubMedCrossRefGoogle Scholar
  3. 3.
    Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009;27:313–38.PubMedCrossRefGoogle Scholar
  4. 4.
    Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 2005;78:1043–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011;25:2559–72.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22:327–34.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24:392–407.CrossRefGoogle Scholar
  8. 8.
    Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL-10 gene and further characterization of the 5’ flanking sequence. Immunogenetics. 1997;46:120–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Stanilova SA, Miteva LD, Karakolev ZT, Stefanov CS. Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med. 2006;32:260–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Larsson L, Rymo L, Berglundh T. Sp1 binds to the G allele of the-1087 polymorphism in the IL-10 promoter and promotes IL-10 mRNA transcription and protein production. Genes Immunol. 2010;11:181–7.CrossRefGoogle Scholar
  12. 12.
    Stanilova S. Cytokine gene polymorphisms in colorectal cancer. In Ettarh R editor. Colorectal cancer biology - from genes to tumor. InTech; 2012. p59-78Google Scholar
  13. 13.
    Zhang YM, Zhou XC, Xu Z, Tang CJ. Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. Genet Mol Res. 2012;11:3389–97.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilkening S, Tavelin B, Canzian F, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008;29:1202–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Cacev T, Radosevic S, Krizanac S, Kapitanovic S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis. 2008;29:1572–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Crivello A, Giacalone A, Vaglica M, et al. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci. 2006;1089:98–103.PubMedCrossRefGoogle Scholar
  17. 17.
    Tsilidis KK, Helzlsouer KJ, Smith MW, et al. Association of common polymorphism in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009;20:1739–51.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Burada F, Dumitrescu T, Nicoli R, Ciurea ME, Rogoveanu I, Ioana M. Cytokine promoter polymorphisms and risk of colorectal cancer. Clin Lab. 2013;59:773–9.PubMedGoogle Scholar
  19. 19.
    Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7:331–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(delta delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Stanilov N, Miteva L, Deliysky T, Jovchev J, Stanilova S. Advanced colorectal cancer is associated with enhanced IL-23 and IL −10 serum level. Lab Med. 2010;41:159–63.CrossRefGoogle Scholar
  22. 22.
    Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–18.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32:23–63.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Chichlowski M, Sharp JM, Vanderford DA, Myles MH, Hale LP. Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp Med. 2008;58:534–41.PubMedCentralPubMedGoogle Scholar
  25. 25.
    De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer. 1999;86:1936–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Evans C, Morrison I, Heriot AG, et al. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer. 2006;94:1412–9.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Szaflarska A, Szczepanik A, Siedlar M, et al. Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res. 2009;29:5005–12.PubMedGoogle Scholar
  28. 28.
    Miteva L, Stanilova S. The combined effect of interleukin (IL)-10 and IL-12 polymorphisms on induced cytokine production. Hum Immunol. 2008;69:562–6.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Lyuba D. Miteva
    • 1
  • Noyko S. Stanilov
    • 2
    • 3
  • Tashko S. Deliysky
    • 4
  • Spaska A. Stanilova
    • 1
  1. 1.Department of Molecular Biology, Immunology and Medical Genetics, Medical FacultyTrakia UniversityStara ZagoraBulgaria
  2. 2.Department of Neurosurgery, Surgery and Urology; Medical FacultyTrakia UniversityStara ZagoraBulgaria
  3. 3.Colorectal Surgery UnitThe Royal London HospitalLondonUK
  4. 4.Oncology CenterUniversity School of MedicinePlevenBulgaria

Personalised recommendations